Brief: Hoth Therapeutics Reports Positive Ht-001 Pk, Safety, And Clinical Activity Data In Cancer Patients With Egfr Therapy
24/03/2026 12:17
March 24 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS REPORTS POSITIVE HT-001 PK, SAFETY, AND CLINICAL ACTIVITY DATA IN CANCER PATIENTS WITH EGFR THERAPY-ASSOCIATED SKIN TOXICITIES SHOWING ~77% INCREASE IN DRUG EXPOSURE AND MINIMAL SYSTEMIC ABSORPTION HOTH THERAPEUTICS INC - HT-001 SHOWS NO SERIOUS ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES Source text: ID:nPn9fXs58a Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology